25 results on '"van de Loo, Bob"'
Search Results
2. The Effect of Genetic Variations in the Vitamin D Receptor Gene on the Course of Depressive Symptoms
- Author
-
Wenzler, Ana Neeltje, van de Loo, Bob, van der Velde, Natalie, and van Schoor, Natasja M.
- Published
- 2024
- Full Text
- View/download PDF
3. Clinical Decision Support Systems in Hospitalized Older Patients: An Exploratory Analysis in a Real-Life Clinical Setting
- Author
-
Linkens, Aimée E. M. J. H., Kurstjens, Dennis, Zwietering, N. Anne, Milosevic, Vanja, Hurkens, Kim P. G. M., van Nie, Noémi, van de Loo, Bob P. A., van der Kuy, P. Hugo M., and Spaetgens, Bart
- Published
- 2023
- Full Text
- View/download PDF
4. Validation of the ADFICE_IT Models for Predicting Falls and Recurrent Falls in Geriatric Outpatients
- Author
-
van de Loo, Bob, Heymans, Martijn W., Medlock, Stephanie, Boyé, Nicole D.A., van der Cammen, Tischa J.M., Hartholt, Klaas A., Emmelot-Vonk, Marielle H., Mattace-Raso, Francesco U.S., Abu-Hanna, Ameen, van der Velde, Nathalie, and van Schoor, Natasja M.
- Published
- 2023
- Full Text
- View/download PDF
5. Control in the Hospital by Extensive Clinical rules for Unplanned hospitalizations in older Patients (CHECkUP); study design of a multicentre randomized study
- Author
-
Linkens, Aimée E. M. J. H., Milosevic, Vanja, van Nie, Noémi, Zwietering, Anne, de Leeuw, Peter W., van den Akker, Marjan, Schols, Jos M. G. A., Evers, Silvia M. A. A., Gonzalvo, Carlota Mestres, Winkens, Bjorn, van de Loo, Bob P. A., de Wolf, Louis, Peeters, Lucretia, de Ree, Monique, Spaetgens, Bart, Hurkens, Kim P. G. M., and van der Kuy, Hugo M.
- Published
- 2022
- Full Text
- View/download PDF
6. Development of the ADFICE_IT clinical decision support system to assist deprescribing of fall-risk increasing drugs: A user-centered design approach.
- Author
-
Groos, Sara S., de Wildt, Kelly K., van de Loo, Bob, Linn, Annemiek J., Medlock, Stephanie, Shaw, Kendrick M., Herman, Eric K., Seppala, Lotta J., Ploegmakers, Kim J., van Schoor, Natasja M., van Weert, Julia C. M., and van der Velde, Nathalie
- Subjects
CLINICAL decision support systems ,ELECTRONIC health records ,DEPRESCRIBING ,WEBSITES ,MEDICATION therapy management - Abstract
Introduction: Deprescribing fall-risk increasing drugs (FRIDs) is promising for reducing the risk of falling in older adults. Applying appropriate deprescribing in practice can be difficult due to the outcome uncertainties associated with stopping FRIDs. The ADFICE_IT intervention addresses this complexity with a clinical decision support system (CDSS) that facilitates optimum deprescribing of FRIDs by using a fall-risk prediction model, aggregation of deprescribing guidelines, and joint medication management. Methods: The development process of the CDSS is described in this paper. Development followed a user-centered design approach in which users and experts were involved throughout each phase. In phase I, a prototype of the CDSS was developed which involved a literature and systematic review, European survey (n = 581), and semi-structured interviews with clinicians (n = 19), as well as the aggregation and testing of deprescribing guidelines and the development of the fall-risk prediction model. In phase II, the feasibility of the CDSS was tested by means of two usability testing rounds with users (n = 11). Results: The final CDSS consists of five web pages. A connection between the Electronic Health Record allows for the retrieval of patient data into the CDSS. Key design requirements for the CDSS include easy-to-use features for fast-paced clinical environments, actionable deprescribing recommendations, information transparency, and visualization of the patient's fall-risk estimation. Key elements for the software include a modular architecture, open source, and good security. Conclusion: The ADFICE_IT CDSS supports physicians in deprescribing FRIDs optimally to prevent falls in older patients. Due to continuous user and expert involvement, each new feedback round led to an improved version of the system. Currently, a cluster-randomized controlled trial with process evaluation at hospitals in the Netherlands is being conducted to test the effect of the CDSS on falls. The trial is registered with ClinicalTrials.gov (date; 7-7-2022, identifier: NCT05449470). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Development of the ADFICE_IT clinical decision support system to assist deprescribing of fall-risk increasing drugs: A user-centered design approach
- Author
-
Groos, Sara S., primary, de Wildt, Kelly K., additional, van de Loo, Bob, additional, Linn, Annemiek J., additional, Medlock, Stephanie, additional, Shaw, Kendrick M., additional, Herman, Eric K., additional, Seppala, Lotta J., additional, Ploegmakers, Kim J., additional, van Schoor, Natasja M., additional, van Weert, Julia C. M., additional, and van der Velde, Nathalie, additional
- Published
- 2024
- Full Text
- View/download PDF
8. A systematic review of fall prediction models for community-dwelling older adults: comparison between models based on research cohorts and models based on routinely collected data.
- Author
-
Dormosh, Noman, van de Loo, Bob, Heymans, Martijn W, Schut, Martijn C, Medlock, Stephanie, Schoor, Natasja M van, van der Velde, Nathalie, and Abu-Hanna, Ameen
- Subjects
- *
ACCIDENTAL falls in old age , *MEDICAL information storage & retrieval systems , *STATISTICAL models , *RISK assessment , *PREDICTION models , *INDEPENDENT living , *RECEIVER operating characteristic curves , *RESEARCH funding , *DESCRIPTIVE statistics , *SYSTEMATIC reviews , *MEDLINE , *MEDICAL research , *GERIATRIC assessment , *QUALITY assurance , *EVALUATION - Abstract
Background Prediction models can identify fall-prone individuals. Prediction models can be based on either data from research cohorts (cohort-based) or routinely collected data (RCD-based). We review and compare cohort-based and RCD-based studies describing the development and/or validation of fall prediction models for community-dwelling older adults. Methods Medline and Embase were searched via Ovid until January 2023. We included studies describing the development or validation of multivariable prediction models of falls in older adults (60+). Both risk of bias and reporting quality were assessed using the PROBAST and TRIPOD, respectively. Results We included and reviewed 28 relevant studies, describing 30 prediction models (23 cohort-based and 7 RCD-based), and external validation of two existing models (one cohort-based and one RCD-based). The median sample sizes for cohort-based and RCD-based studies were 1365 [interquartile range (IQR) 426–2766] versus 90 441 (IQR 56 442–128 157), and the ranges of fall rates were 5.4% to 60.4% versus 1.6% to 13.1%, respectively. Discrimination performance was comparable between cohort-based and RCD-based models, with the respective area under the receiver operating characteristic curves ranging from 0.65 to 0.88 versus 0.71 to 0.81. The median number of predictors in cohort-based final models was 6 (IQR 5–11); for RCD-based models, it was 16 (IQR 11–26). All but one cohort-based model had high bias risks, primarily due to deficiencies in statistical analysis and outcome determination. Conclusions Cohort-based models to predict falls in older adults in the community are plentiful. RCD-based models are yet in their infancy but provide comparable predictive performance with no additional data collection efforts. Future studies should focus on methodological and reporting quality. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Effects of a clinical decision support system and patient portal for preventing medication-related falls in older fallers: Protocol of a cluster randomized controlled trial with embedded process and economic evaluations (ADFICE_IT)
- Author
-
de Wildt, Kelly K., primary, van de Loo, Bob, additional, Linn, Annemiek J., additional, Medlock, Stephanie K., additional, Groos, Sara S., additional, Ploegmakers, Kim J., additional, Seppala, Lotta J., additional, Bosmans, Judith E., additional, Abu-Hanna, Ameen, additional, van Weert, Julia C.M., additional, van Schoor, Natasja M., additional, and van der Velde, Nathalie, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Testing the Usability of the ADFICE_IT Patient Portal for improving Shared Decision Making
- Author
-
Groos, Sara, primary, van de Loo, Bob, additional, Medlock, Stephanie, additional, Ploegmakers, Kimberley, additional, van Weert, Julia, additional, van Schoor, Natasja, additional, and van der Velde, Nathalie, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Validation of the ADFICE_IT Models for Predicting Falls and Recurrent Falls in Geriatric Outpatients
- Author
-
van de Loo, Bob (author), Heymans, Martijn W. (author), Medlock, Stephanie (author), Boyé, Nicole D.A. (author), van der Cammen, T.J.M. (author), Hartholt, Klaas A. (author), Emmelot-Vonk, Marielle H. (author), Abu-Hanna, Ameen (author), van Schoor, Natasja M. (author), van de Loo, Bob (author), Heymans, Martijn W. (author), Medlock, Stephanie (author), Boyé, Nicole D.A. (author), van der Cammen, T.J.M. (author), Hartholt, Klaas A. (author), Emmelot-Vonk, Marielle H. (author), Abu-Hanna, Ameen (author), and van Schoor, Natasja M. (author)
- Abstract
Objectives: Before being used in clinical practice, a prediction model should be tested in patients whose data were not used in model development. Previously, we developed the ADFICE_IT models for predicting any fall and recurrent falls, referred as Any_fall and Recur_fall. In this study, we externally validated the models and compared their clinical value to a practical screening strategy where patients are screened for falls history alone. Design: Retrospective, combined analysis of 2 prospective cohorts. Setting and Participants: Data were included of 1125 patients (aged ≥65 years) who visited the geriatrics department or the emergency department. Methods: We evaluated the models' discrimination using the C-statistic. Models were updated using logistic regression if calibration intercept or slope values deviated significantly from their ideal values. Decision curve analysis was applied to compare the models’ clinical value (ie, net benefit) against that of falls history for different decision thresholds. Results: During the 1-year follow-up, 428 participants (42.7%) endured 1 or more falls, and 224 participants (23.1%) endured a recurrent fall (≥2 falls). C-statistic values were 0.66 (95% CI 0.63-0.69) and 0.69 (95% CI 0.65-0.72) for the Any_fall and Recur_fall models, respectively. Any_fall overestimated the fall risk and we therefore updated only its intercept whereas Recur_fall showed good calibration and required no update. Compared with falls history, Any_fall and Recur_fall showed greater net benefit for decision thresholds of 35% to 60% and 15% to 45%, respectively. Conclusions and Implications: The models performed similarly in this data set of geriatric outpatients as in the development sample. This suggests that fall-risk assessment tools that were developed in community-dwelling older adults may perform well in geriatric outpatients. We found that in geriatric outpatients the models have greater clinical value across a wide range of decision thresho, Applied Ergonomics and Design
- Published
- 2023
- Full Text
- View/download PDF
12. Clinical Decision Support Systems in Hospitalized Older Patients:An Exploratory Analysis in a Real-Life Clinical Setting
- Author
-
Linkens, Aimée E.M.J.H., Kurstjens, Dennis, Zwietering, N. Anne, Milosevic, Vanja, Hurkens, Kim P.G.M., van Nie, Noémi, van de Loo, Bob P.A., van der Kuy, P. Hugo M., Spaetgens, Bart, Linkens, Aimée E.M.J.H., Kurstjens, Dennis, Zwietering, N. Anne, Milosevic, Vanja, Hurkens, Kim P.G.M., van Nie, Noémi, van de Loo, Bob P.A., van der Kuy, P. Hugo M., and Spaetgens, Bart
- Abstract
Background: Inappropriate prescribing is associated with negative patient outcomes. In hospitalized patients, the use of Clinical Decision Support Systems (CDSSs) may reduce inappropriate prescribing and thereby improve patient-related outcomes. However, recently published large clinical trials (OPERAM and SENATOR) have shown negative results on the use of CDSSs and patient outcomes and strikingly low acceptance of recommendations. Objective: The purpose of the present study was to investigate the use of a CDSS in a real-life clinical setting of hospitalized older patients. As such, we report on the real-life pattern of this in-hospital implemented CDSS, including (i) whether generated alerts were resolved; (ii) whether a recorded action by the pharmacist led to an improved number of resolved alerts; and (iii) the natural course of generated alerts, in particular of those in the non-intervention group; as these data are largely lacking in current studies. Methods: Hospitalized patients, aged 60 years and older, admitted to Zuyderland Medical Centre, the Netherlands, in 2018 were included. The evaluation of the CDSS was investigated using a database used for standard care. Alongside demographic and clinical data, we also collected the total numbers of CDSS alerts, the number of alerts ‘handled’ by the pharmacist, those that resulted in an action by the pharmacist, and finally the outcome of the alerts at day 1 and day 3 after the alert was generated. Results: A total of 3574 unique hospitalized patients, mean age 76.7 (SD 8.3) years and 53% female, were included. From these patients, 8073 alerts were generated, of which 7907 (97.9% of total) were handled by the pharmacist (day 1). In 51.6% of the alerts handled by the pharmacist, an action was initiated, resulting in 36.1% of the alerts resolved after day 1, compared with 27.3% if the pharmacist did not perform an action (p < 0.001). On day 3, in 52.6% of the alerts an action by the pharmacist was initiated, re
- Published
- 2023
13. Validation of the ADFICE_IT Models for Predicting Falls and Recurrent Falls in Geriatric Outpatients
- Author
-
MS Geriatrie, Circulatory Health, van de Loo, Bob, Heymans, Martijn W, Medlock, Stephanie, Boyé, Nicole D A, van der Cammen, Tischa J M, Hartholt, Klaas A, Emmelot-Vonk, Marielle H, Mattace-Raso, Francesco U S, Abu-Hanna, Ameen, van der Velde, Nathalie, van Schoor, Natasja M, MS Geriatrie, Circulatory Health, van de Loo, Bob, Heymans, Martijn W, Medlock, Stephanie, Boyé, Nicole D A, van der Cammen, Tischa J M, Hartholt, Klaas A, Emmelot-Vonk, Marielle H, Mattace-Raso, Francesco U S, Abu-Hanna, Ameen, van der Velde, Nathalie, and van Schoor, Natasja M
- Published
- 2023
14. Effects of a clinical decision support system and patient portal for preventing medication-related falls in older fallers: Protocol of a cluster randomized controlled trial with embedded process and economic evaluations (ADFICE_IT).
- Author
-
de Wildt, Kelly K., van de Loo, Bob, Linn, Annemiek J., Medlock, Stephanie K., Groos, Sara S., Ploegmakers, Kim J., Seppala, Lotta J., Bosmans, Judith E., Abu-Hanna, Ameen, van Weert, Julia C. M., van Schoor, Natasja M., and van der Velde, Nathalie
- Subjects
- *
CLINICAL decision support systems , *PATIENT portals , *CLUSTER randomized controlled trials , *MEDICAL informatics , *MULTILEVEL models - Abstract
Background: Falls are the leading cause of injury-related mortality and hospitalization among adults aged ≥ 65 years. An important modifiable fall-risk factor is use of fall-risk increasing drugs (FRIDs). However, deprescribing is not always attempted or performed successfully. The ADFICE_IT trial evaluates the combined use of a clinical decision support system (CDSS) and a patient portal for optimizing the deprescribing of FRIDs in older fallers. The intervention aims to optimize and enhance shared decision making (SDM) and consequently prevent injurious falls and reduce healthcare-related costs. Methods: A multicenter, cluster-randomized controlled trial with process evaluation will be conducted among hospitals in the Netherlands. We aim to include 856 individuals aged ≥ 65 years that visit the falls clinic due to a fall. The intervention comprises the combined use of a CDSS and a patient portal. The CDSS provides guideline-based advice with regard to deprescribing and an individual fall-risk estimation, as calculated by an embedded prediction model. The patient portal provides educational information and a summary of the patient's consultation. Hospitals in the control arm will provide care-as-usual. Fall-calendars will be used for measuring the time to first injurious fall (primary outcome) and secondary fall outcomes during one year. Other measurements will be conducted at baseline, 3, 6, and 12 months and include quality of life, cost-effectiveness, feasibility, and shared decision-making measures. Data will be analyzed according to the intention-to-treat principle. Difference in time to injurious fall between the intervention and control group will be analyzed using multilevel Cox regression. Discussion: The findings of this study will add valuable insights about how digital health informatics tools that target physicians and older adults can optimize deprescribing and support SDM. We expect the CDSS and patient portal to aid in deprescribing of FRIDs, resulting in a reduction in falls and related injuries. Trial registration: ClinicalTrials.gov NCT05449470 (7-7-2022). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Development of the ADFICE_IT Models for Predicting Falls and Recurrent Falls in Community-Dwelling Older Adults:Pooled Analyses of European Cohorts With Special Attention to Medication
- Author
-
Van De Loo, Bob, Seppala, Lotta J., Van Der Velde, Nathalie, Medlock, Stephanie, Denkinger, Michael, De Groot, Lisette C.P.G.M., Kenny, Rose Anne, Moriarty, Frank, Rothenbacher, Dietrich, Stricker, Bruno, Uitterlinden, André, Abu-Hanna, Ameen, Heymans, Martijn W., Van Schoor, Natasja, Van De Loo, Bob, Seppala, Lotta J., Van Der Velde, Nathalie, Medlock, Stephanie, Denkinger, Michael, De Groot, Lisette C.P.G.M., Kenny, Rose Anne, Moriarty, Frank, Rothenbacher, Dietrich, Stricker, Bruno, Uitterlinden, André, Abu-Hanna, Ameen, Heymans, Martijn W., and Van Schoor, Natasja
- Abstract
Background: Use of fall prevention strategies requires detection of high-risk patients. Our goal was to develop prediction models for falls and recurrent falls in community-dwelling older adults and to improve upon previous models by using a large, pooled sample and by considering a wide range of candidate predictors, including medications. Methods: Harmonized data from 2 Dutch (LASA, B-PROOF) and 1 German cohort (ActiFE Ulm) of adults aged ≥65 years were used to fit 2 logistic regression models: one for predicting any fall and another for predicting recurrent falls over 1 year. Model generalizability was assessed using internal-external cross-validation. Results: Data of 5 722 participants were included in the analyses, of whom 1 868 (34.7%) endured at least 1 fall and 702 (13.8%) endured a recurrent fall. Positive predictors for any fall were: educational status, depression, verbal fluency, functional limitations, falls history, and use of antiepileptics and drugs for urinary frequency and incontinence; negative predictors were: body mass index (BMI), grip strength, systolic blood pressure, and smoking. Positive predictors for recurrent falls were: educational status, visual impairment, functional limitations, urinary incontinence, falls history, and use of anti-Parkinson drugs, antihistamines, and drugs for urinary frequency and incontinence; BMI was a negative predictor. The average C-statistic value was 0.65 for the model for any fall and 0.70 for the model for recurrent falls. Conclusion: Compared with previous models, the model for recurrent falls performed favorably while the model for any fall performed similarly. Validation and optimization of the models in other populations are warranted.
- Published
- 2022
16. Development of the ADFICE_IT Models for Predicting Falls and Recurrent Falls in Community-Dwelling Older Adults : Pooled Analyses of European Cohorts With Special Attention to Medication
- Author
-
Van De Loo, Bob, Seppala, Lotta J., Van Der Velde, Nathalie, Medlock, Stephanie, Denkinger, Michael, De Groot, Lisette C.P.G.M., Kenny, Rose Anne, Moriarty, Frank, Rothenbacher, Dietrich, Stricker, Bruno, Uitterlinden, André, Abu-Hanna, Ameen, Heymans, Martijn W., Van Schoor, Natasja, Van De Loo, Bob, Seppala, Lotta J., Van Der Velde, Nathalie, Medlock, Stephanie, Denkinger, Michael, De Groot, Lisette C.P.G.M., Kenny, Rose Anne, Moriarty, Frank, Rothenbacher, Dietrich, Stricker, Bruno, Uitterlinden, André, Abu-Hanna, Ameen, Heymans, Martijn W., and Van Schoor, Natasja
- Abstract
Background: Use of fall prevention strategies requires detection of high-risk patients. Our goal was to develop prediction models for falls and recurrent falls in community-dwelling older adults and to improve upon previous models by using a large, pooled sample and by considering a wide range of candidate predictors, including medications. Methods: Harmonized data from 2 Dutch (LASA, B-PROOF) and 1 German cohort (ActiFE Ulm) of adults aged ≥65 years were used to fit 2 logistic regression models: one for predicting any fall and another for predicting recurrent falls over 1 year. Model generalizability was assessed using internal-external cross-validation. Results: Data of 5 722 participants were included in the analyses, of whom 1 868 (34.7%) endured at least 1 fall and 702 (13.8%) endured a recurrent fall. Positive predictors for any fall were: educational status, depression, verbal fluency, functional limitations, falls history, and use of antiepileptics and drugs for urinary frequency and incontinence; negative predictors were: body mass index (BMI), grip strength, systolic blood pressure, and smoking. Positive predictors for recurrent falls were: educational status, visual impairment, functional limitations, urinary incontinence, falls history, and use of anti-Parkinson drugs, antihistamines, and drugs for urinary frequency and incontinence; BMI was a negative predictor. The average C-statistic value was 0.65 for the model for any fall and 0.70 for the model for recurrent falls. Conclusion: Compared with previous models, the model for recurrent falls performed favorably while the model for any fall performed similarly. Validation and optimization of the models in other populations are warranted.
- Published
- 2022
17. Control in the Hospital by Extensive Clinical rules for Unplanned hospitalizations in older Patients (CHECkUP): study design of a multicentre randomized study
- Author
-
Linkens, Aimée E.M.J.H., Milosevic, Vanja, van Nie, Noémi, Zwietering, Anne, de Leeuw, Peter W., van den Akker, Marjan, Schols, Jos M.G.A., Evers, Silvia M.A.A., Gonzalvo, Carlota Mestres, Winkens, Bjorn, van de Loo, Bob P.A., de Wolf, Louis, Peeters, Lucretia, de Ree, Monique, Spaetgens, Bart, Hurkens, Kim P.G.M., van der Kuy, Hugo M., Linkens, Aimée E.M.J.H., Milosevic, Vanja, van Nie, Noémi, Zwietering, Anne, de Leeuw, Peter W., van den Akker, Marjan, Schols, Jos M.G.A., Evers, Silvia M.A.A., Gonzalvo, Carlota Mestres, Winkens, Bjorn, van de Loo, Bob P.A., de Wolf, Louis, Peeters, Lucretia, de Ree, Monique, Spaetgens, Bart, Hurkens, Kim P.G.M., and van der Kuy, Hugo M.
- Abstract
Background: Due to ageing of the population the incidence of multimorbidity and polypharmacy is rising. Polypharmacy is a risk factor for medication-related (re)admission and therefore places a significant burden on the healthcare system. The reported incidence of medication-related (re)admissions varies widely due to the lack of a clear definition. Some medications are known to increase the risk for medication-related admission and are therefore published in the triggerlist of the Dutch guideline for Polypharmacy in older patients. Different interventions to support medication optimization have been studied to reduce medication-related (re)admissions. However, the optimal template of medication optimization is still unknown, which contributes to the large heterogeneity of their effect on hospital readmissions. Therefore, we implemented a clinical decision support system (CDSS) to optimize medication lists and investigate whether continuous use of a CDSS reduces the number of hospital readmissions in older patients, who previously have had an unplanned probably medication-related hospitalization. Methods: The CHECkUP study is a multicentre randomized study in older (≥60 years) patients with an unplanned hospitalization, polypharmacy (≥5 medications) and using at least two medications from the triggerlist, from Zuyderland Medical Centre and Maastricht University Medical Centre+ in the Netherlands. Patients will be randomized. The intervention consists of continuous (weekly) use of a CDSS, which generates a Medication Optimization Profile, which will be sent to the patient’s general practitioner and pharmacist. The control group will receive standard care. The primary outcome is hospital readmission within 1 year after study inclusion. Secondary outcomes are one-year mortality, number of emergency department visits, nursing home admissions, time to hospital readmissions and we will evaluate the quality of life and socio-economic status. Discussion: This study is ex
- Published
- 2022
18. Development of the ADFICE_IT Models for Predicting Falls and Recurrent Falls in Community-Dwelling Older Adults: Pooled Analyses of European Cohorts With Special Attention to Medication
- Author
-
van de Loo, Bob, primary, Seppala, Lotta J, additional, van der Velde, Nathalie, additional, Medlock, Stephanie, additional, Denkinger, Michael, additional, de Groot, Lisette CPGM, additional, Kenny, Rose-Anne, additional, Moriarty, Frank, additional, Rothenbacher, Dietrich, additional, Stricker, Bruno, additional, Uitterlinden, André, additional, Abu-Hanna, Ameen, additional, Heymans, Martijn W, additional, and van Schoor, Natasja, additional
- Published
- 2022
- Full Text
- View/download PDF
19. Additional file 1 of Control in the Hospital by Extensive Clinical rules for Unplanned hospitalizations in older Patients (CHECkUP); study design of a multicentre randomized study
- Author
-
Linkens, Aim��e E. M. J. H., Milosevic, Vanja, van Nie, No��mi, Zwietering, Anne, de Leeuw, Peter W., van den Akker, Marjan, Schols, Jos M. G. A., Evers, Silvia M. A. A., Gonzalvo, Carlota Mestres, Winkens, Bjorn, van de Loo, Bob P. A., de Wolf, Louis, Peeters, Lucretia, de Ree, Monique, Spaetgens, Bart, Hurkens, Kim P. G. M., and van der Kuy, Hugo M.
- Subjects
Data_FILES - Abstract
Additional file 1: Table S1. Overview of the clinical rules.
- Published
- 2022
- Full Text
- View/download PDF
20. Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET):an international, multicentre, retrospective, observational cohort study
- Author
-
Sablerolles, Roos S G, Lafeber, Melvin, van Kempen, Janneke A L, van de Loo, Bob P A, Boersma, Eric, Rietdijk, Wim J R, Polinder-Bos, Harmke A, Mooijaart, Simon P, van der Kuy, Hugo, Versmissen, Jorie, Faes, Miriam C, Sablerolles, Roos S G, Lafeber, Melvin, van Kempen, Janneke A L, van de Loo, Bob P A, Boersma, Eric, Rietdijk, Wim J R, Polinder-Bos, Harmke A, Mooijaart, Simon P, van der Kuy, Hugo, Versmissen, Jorie, and Faes, Miriam C
- Abstract
Background: During the COVID-19 pandemic, the scarcity of resources has necessitated triage of critical care for patients with the disease. In patients aged 65 years and older, triage decisions are regularly based on degree of frailty measured by the Clinical Frailty Scale (CFS). However, the CFS could also be useful in patients younger than 65 years. We aimed to examine the association between CFS score and hospital mortality and between CFS score and admission to intensive care in adult patients of all ages with COVID-19 across Europe. Methods: This analysis was part of the COVID Medication (COMET) study, an international, multicentre, retrospective observational cohort study in 63 hospitals in 11 countries in Europe. Eligible patients were aged 18 years and older, had been admitted to hospital, and either tested positive by PCR for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or were judged to have a high clinical likelihood of having SARS-CoV-2 infection by the local COVID-19 expert team. CFS was used to assess level of frailty: fit (CFS 1–3), mildly frail (CFS 4–5), or frail (CFS 6–9). The primary outcome was hospital mortality. The secondary outcome was admission to intensive care. Data were analysed using a multivariable binary logistic regression model adjusted for covariates (age, sex, number of drugs prescribed, and type of drug class as a proxy for comorbidities). Findings: Between March 30 and July 15, 2020, 2434 patients (median age 68 years [IQR 55–77]; 1480 [61%] men, 954 [30%] women) had CFS scores available and were included in the analyses. In the total sample and in patients aged 65 years and older, frail patients and mildly frail patients had a significantly higher risk of hospital mortality than fit patients (total sample: CFS 6–9 vs CFS 1–3 odds ratio [OR] 2·71 [95% CI 2·04–3·60], p<0·0001 and CFS 4–5 vs CFS 1–3 OR 1·54 [1·16–2·06], p=0·0030; age
- Published
- 2021
21. Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET): an international, multicentre, retrospective, observational cohort study
- Author
-
Sablerolles, Roos S G, primary, Lafeber, Melvin, additional, van Kempen, Janneke A L, additional, van de Loo, Bob P A, additional, Boersma, Eric, additional, Rietdijk, Wim J R, additional, Polinder-Bos, Harmke A, additional, Mooijaart, Simon P, additional, van der Kuy, Hugo, additional, Versmissen, Jorie, additional, Faes, Miriam C, additional, Agnoletto, LA, additional, Aleman, J, additional, Andreassi, S, additional, Andrews, LM, additional, Ashfield, L, additional, Bell, H, additional, Bengaard, AKB, additional, Berlinghini, SB, additional, Bini, KB, additional, Bisoffi, ZB, additional, Blum, KB, additional, Boemaars, E, additional, Boni, GB, additional, Bosch, TM, additional, Bosma, BE, additional, Boutkourt, F, additional, Bufarini, C, additional, Bulsink, A, additional, Cabuk, RC, additional, Callens, GC, additional, Candela, MC, additional, Canonici, MC, additional, Capone, EC, additional, Carmo, IC, additional, Caruso, FC, additional, Chessa, PC, additional, Cohet, GC, additional, Cornelissen-Wesseling, I, additional, Crommentuijn, KML, additional, de Stoppelaar, FM, additional, de Wit, HAJM, additional, Deben, DS, additional, Derijks, LJJ, additional, Di Carlo, MDC, additional, Diepstraten, J, additional, Dilek, B, additional, Duchek-Mann, DMK, additional, Ebbens, MM, additional, Ellerbroek, LJ, additional, Ezinga, M, additional, Falcao, MF, additional, Falcao, FF, additional, Fantini, LF, additional, Farinha, HF, additional, Filius, PMG, additional, Fitzhugh, NJ, additional, Fleming, G, additional, Forsthuber, TF, additional, Gambarelli, GG, additional, Gambera, MG, additional, García Yubero, CGY, additional, Getrouw, Z, additional, Ghazarian, CN, additional, Goodfellow, N, additional, Gorgas, MQG, additional, Grinta, RG, additional, Guda, K, additional, Haider, DH, additional, Hanley, J, additional, Heitzeneder, KH, additional, Hemminga, WL, additional, Hendriksen, LC, additional, Hilarius, DL, additional, Hogenhuis, FEF, additional, Hoogendoorn-de Graaf, IC, additional, Houlind, MBH, additional, Huebler, MAH, additional, Hurkens, KPGM, additional, Janssen, PKC, additional, Jong, E, additional, Kappers, MHW, additional, Keijzers, KFM, additional, Kemogni, MK, additional, Kemper, EM, additional, Kranenburg, RA, additional, Krens, LL, additional, Le Grand, JL G, additional, Liang, J, additional, Lim, S, additional, Lindner, NL, additional, Loche, EL, additional, Lubich, AL, additional, Maat, B, additional, Maesano, CM, additional, Maiworm, AM, additional, Maragna, M, additional, Marchesini, FM, additional, Martignoni, IM, additional, Martini, G M, additional, Masini, CM, additional, Mc Menamin, R, additional, Mendes, DM, additional, Miarons, M, additional, Moorlag, R, additional, Müller, MR, additional, Nagele, FN, additional, Nemec, KN, additional, Oka, GO, additional, Otten-Helmers, AG, additional, Pagliarino, SP, additional, Pappalardo, FP, additional, Patel, M, additional, Peverini, PM, additional, Pieraccini, FP, additional, Platania, EMP, additional, Pons-Kerjean, NPK, additional, Portillo Horcajada, LPH, additional, Rametta, GR, additional, Rijo, JR, additional, Roelofsen, EE, additional, Roobol-Meuwese, E, additional, Rossi, LR, additional, Russel, SAH, additional, Safipour, Z, additional, Salaffi, FS, additional, Saleh, L, additional, Schimizzi, AMS, additional, Schols, JMGA, additional, Schwap, MS, additional, Scott, MG, additional, Slijfer, EAM, additional, Slob, EMA, additional, Soares, JS, additional, Solano, MS, additional, Sombogaard, F, additional, Stemer, GS, additional, Tardella, MT, additional, ter Horst, PGJ, additional, Tessari, RT, additional, Tournoy, J, additional, van den Berg, RB, additional, Van der Linden, L, additional, van der Linden, PD, additional, van Dijk, SC, additional, Van Etten, RW, additional, van Haelst, IMM, additional, van Heuckelum, M, additional, van Kan, HJM, additional, van Nieuwkoop, C, additional, van Onzenoort, HAW, additional, van Wijngaarden, P, additional, Verdonk, JDJ, additional, Verri, Fv, additional, Verstijnen, JAMC, additional, Veyrier, MV, additional, Viegas, EV, additional, Visser, LE, additional, Vos, A, additional, Vromen, MAM, additional, Wierenga, PC, additional, Wong, DR, additional, Zenico, CZ, additional, and Zuppini, TZ, additional
- Published
- 2021
- Full Text
- View/download PDF
22. COvid MEdicaTion (COMET) study:protocol for a cohort study
- Author
-
Sablerolles, Roos S. G., Hogenhuis, Freija E. F., Lafeber, Melvin, van de Loo, Bob P. A., Borgsteede, Sander D., Boersma, Eric, Versmissen, Jorie, van der Kuy, Hugo M., Sablerolles, Roos S. G., Hogenhuis, Freija E. F., Lafeber, Melvin, van de Loo, Bob P. A., Borgsteede, Sander D., Boersma, Eric, Versmissen, Jorie, and van der Kuy, Hugo M.
- Abstract
Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.
- Published
- 2020
23. O.O.6.1 - Testing the Usability of the ADFICE_IT Patient Portal for improving Shared Decision Making: Presenter(s): Kelly de Wildt, Amsterdam UMC, Netherlands; Annemiek Linn, University of Amsterdam, Netherlands
- Author
-
Groos, Sara, van de Loo, Bob, Medlock, Stephanie, Ploegmakers, Kimberley, van Weert, Julia, van Schoor, Natasja, and van der Velde, Nathalie
- Published
- 2023
- Full Text
- View/download PDF
24. COvid MEdicaTion (COMET) study: protocol for a cohort study
- Author
-
Sablerolles, Roos S G, primary, Hogenhuis, Freija E F, additional, Lafeber, Melvin, additional, van de Loo, Bob P A, additional, Borgsteede, Sander D, additional, Boersma, Eric, additional, Versmissen, Jorie, additional, and van der Kuy, Hugo M, additional
- Published
- 2020
- Full Text
- View/download PDF
25. No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study.
- Author
-
Sablerolles RSG, Hogenhuis FEF, Lafeber M, van de Loo BPA, Borgsteede SD, Boersma E, Versmissen J, and van der Kuy H
- Subjects
- Angiotensin Receptor Antagonists adverse effects, Angiotensin-Converting Enzyme Inhibitors adverse effects, Hospitals, Humans, Retrospective Studies, SARS-CoV-2, COVID-19, Hypertension
- Abstract
Since the outbreak of SARS-CoV-2, also known as COVID-19, conflicting theories have circulated on the influence of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) on incidence and clinical course of COVID-19, but data are scarce. The COvid MEdicaTion (COMET) study is an observational, multinational study that focused on the clinical course of COVID-19 (i.e. hospital mortality and intensive care unit [ICU] admission), and included COVID-19 patients who were registered at the emergency department or admitted to clinical wards of 63 participating hospitals. Pharmacists, clinical pharmacologists or treating physicians collected data on medication prescribed prior to admission. The association between the medication and composite clinical endpoint, including mortality and ICU admission, was analysed by multivariable logistic regression models to adjust for potential confounders. A total of 4870 patients were enrolled. ACEi were used by 847 (17.4%) patients and ARB by 761 (15.6%) patients. No significant association was seen with ACEi and the composite endpoint (adjusted odds ratio [OR] 0.94; 95% confidence interval [CI] 0.79 to 1.12), mortality (OR 1.03; 95%CI 0.84 to 1.27) or ICU admission (OR 0.96; 95%CI 0.78 to 1.19) after adjustment for covariates. Similarly, no association was observed between ARB and the composite endpoint (OR 1.09; 95%CI 0.90 to 1.30), mortality (OR 1.12; OR 0.90 to 1.39) or ICU admission (OR 1.21; 95%CI 0.98 to 1.49). In conclusion, we found no evidence of a harmful or beneficial effect of ACEi or ARB use prior to hospital admission on ICU admission or hospital mortality., (© 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.